» Articles » PMID: 31781737

Stratification of Atypical Intraepithelial Prostatic Lesions Based on Basal Cell and Architectural Patterns

Overview
Specialty Pathology
Date 2019 Nov 30
PMID 31781737
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: High-grade prostatic intraepithelial neoplasia (HPIN) and atypical cribriform lesion of the prostate are considered the precursors or associators of invasive prostate cancer (iPCa). Given loss of basal cells being the hallmark of iPCa, we hypothesized that a subset of these atypical intraepithelial lesions (AILs) with sparse basal cells can be classified as prostatic intraepithelial carcinoma (PIC) with frequent iPCa association and that different morphologic patterns of PIC are associated with specific Gleason (G) patterns and scores for iPCa.

Methods: We stratified 153 foci of AILs from 110 patients based on the integrity of the basal cell layer and architectural patterns and their association with iPCa.

Results: We demonstrated that AILs could be stratified into usual HPIN (intact basal cell layer and simple patterns) with low-risk of iPCa association and PIC (sparse basal cell layer) with high risk of iPCa association. Furthermore, PIC could be divided into low-grade (simple patterns and associated with G3 and G3/4 iPCa) and high-grade PIC (complex patterns and associated with G4 and G3/4/5 iPCa).

Conclusions: Such stratification is of great clinical significance and instrumental to clinical patient management. It not only increases the predictability of AILs for iPCa but also accommodates a clinical scenario for lesions with features of intraductal carcinoma when iPCa is not found, particularly in biopsies.

Citing Articles

Intraductal Carcinoma of the Prostate versus Simulants: A Differential Diagnosis Growing in Clinical Impact.

Smith S, Wobker S Cancers (Basel). 2024; 16(6).

PMID: 38539432 PMC: 10968618. DOI: 10.3390/cancers16061097.


Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.

Watson M, Berger P, Banerjee K, Frank S, Tang L, Ganguly S Oncogene. 2021; 40(18):3260-3272.

PMID: 33846571 PMC: 10760404. DOI: 10.1038/s41388-021-01772-y.


Are we ready to include invasive cribriform and intraductal carcinoma into the prostate cancer grade grouping system?.

Xiao G, Sherrod A Transl Androl Urol. 2020; 9(5):2292-2295.

PMID: 33209697 PMC: 7658155. DOI: 10.21037/tau-20-845.